Last reviewed 2026-05-26 · How we verify

RVF MP-12

U.S. Army Medical Research and Development Command · Phase 2 active Biologic ✓ Verified May 2026

RVF MP-12 is a Biologic drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 2 development.

The RVF MP-12 is a live-attenuated vaccine used to study the safety, immunogenicity, and genetic drift in humans. It is a small molecule intervention, specifically a derivative of BCX4430, used to investigate Rift Valley Fever.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RVF MP-12
Sponsor	U.S. Army Medical Research and Development Command
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RVF MP-12 CI brief — competitive landscape report
RVF MP-12 updates RSS · CI watch RSS
U.S. Army Medical Research and Development Command portfolio CI

Frequently asked questions about RVF MP-12

What is RVF MP-12?

RVF MP-12 is a Biologic drug developed by U.S. Army Medical Research and Development Command.

Who makes RVF MP-12?

RVF MP-12 is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).

What development phase is RVF MP-12 in?

RVF MP-12 is in Phase 2.

Manufacturer: U.S. Army Medical Research and Development Command — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing